This Information Collection Request
(ICR) supports agency guidance. The guidance document provides
recommendations for generic drug manufacturers and related industry
who wish to submit a controlled correspondence related to generic
drug development to the Food and Drug Administration (FDA). The
guidance document supports FDA's commitments under the Generic Drug
User Fee Amendments of 2012 (GDUFA).